正在招募
试验总结
一项开放标签、随机、3期研究，旨在评估 MK-2870 单药及联合 帕博利珠单抗 对比 医生选择治疗 在 激素受体阳性/人表皮生长因子受体2阴性（HR+/HER2-）不可切除局部晚期或转移性乳腺癌 受试者中的疗效与安全性。
Who can participate
Clinical trials can have restrictive criteria of who can and can’t participate, talk to your healthcare provider if you are interested in this clinical trial.